Comparing Allurion Technologies (ALUR) & Its Rivals

Allurion Technologies (NYSE:ALUR) is one of 233 public companies in the “Surgical & medical instruments” industry, but how does it contrast to its rivals? We will compare Allurion Technologies to similar companies based on the strength of its earnings, institutional ownership, dividends, profitability, valuation, analyst recommendations and risk.

Valuation & Earnings

This table compares Allurion Technologies and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Allurion Technologies	$53.47 million	-$80.61 million	-0.68
Allurion Technologies Competitors	$1.04 billion	$3.90 million	-4,368.47

Allurion Technologies’ rivals have higher revenue and earnings than Allurion Technologies. Allurion Technologies is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Allurion Technologies and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-117.30%	N/A	-85.06%
Allurion Technologies Competitors	-627.86%	-133.35%	-27.87%

Insider & Institutional Ownership

21.4% of Allurion Technologies shares are owned by institutional investors. Comparatively, 48.5% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 20.0% of Allurion Technologies shares are owned by company insiders. Comparatively, 15.2% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

Allurion Technologies has a beta of -0.22, suggesting that its stock price is 122% less volatile than the S&P 500. Comparatively, Allurion Technologies’ rivals have a beta of 0.85, suggesting that their average stock price is 15% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Allurion Technologies and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	0	0	2	0	3.00
Allurion Technologies Competitors	1670	4450	8636	232	2.50

Allurion Technologies currently has a consensus target price of $5.00, suggesting a potential upside of 93.05%. As a group, “Surgical & medical instruments” companies have a potential upside of 28.41%. Given Allurion Technologies’ stronger consensus rating and higher possible upside, equities analysts plainly believe Allurion Technologies is more favorable than its rivals.

Summary

Allurion Technologies beats its rivals on 7 of the 13 factors compared.

About Allurion Technologies

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.